BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 20432965)

  • 21. Rejection episodes after liver transplantation during primary immunosuppression with FK506 or a cyclosporine-based regimen: a controlled, prospective, randomized trial.
    Jonas S; Kling N; Bechstein WO; Blumhardt G; Lohmann R; Lobeck H; Neuhaus P
    Clin Transplant; 1995 Oct; 9(5):406-14. PubMed ID: 8541635
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
    Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
    Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of early posttransplantation prednisone and calcineurin inhibitor dosages on the incidence of new-onset diabetes.
    Burroughs TE; Lentine KL; Takemoto SK; Swindle J; Machnicki G; Hardinger K; Brennan DC; Irish WD; Schnitzler MA
    Clin J Am Soc Nephrol; 2007 May; 2(3):517-23. PubMed ID: 17699459
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus.
    Fairbanks KD; Eustace JA; Fine D; Thuluvath PJ
    Liver Transpl; 2003 Oct; 9(10):1079-85. PubMed ID: 14526403
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical insights for cancer outcomes in renal transplant patients.
    Alberú J
    Transplant Proc; 2010 Nov; 42(9 Suppl):S36-40. PubMed ID: 21095450
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus.
    Levy G; Grazi GL; Sanjuan F; Wu Y; Mühlbacher F; Samuel D; Friman S; Jones R; Cantisani G; Villamil F; Cillo U; Clavien PA; Klintmalm G; Otto G; Pollard S; McCormick PA
    Liver Transpl; 2006 Oct; 12(10):1464-72. PubMed ID: 17004259
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies.
    Mathew T; Kreis H; Friend P
    Clin Transplant; 2004 Aug; 18(4):446-9. PubMed ID: 15233824
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Coadministration of ketoconazole and cyclosporine for kidney transplant recipients: long-term follow-up and study of metabolic consequences.
    Sobh MA; Hamdy AF; El Agroudy AE; El Sayed K; El-Diasty T; Bakr MA; Ghoneim MA
    Am J Kidney Dis; 2001 Mar; 37(3):510-7. PubMed ID: 11228175
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acquired haemophilia A. First line treatment with calcineurin inhibitors and steroid pulses: a 10-year follow-up study.
    Pardos-Gea J; Altisent C; Parra R; Vilardell-Tarrès M; Ordi-Ros J
    Haemophilia; 2012 Sep; 18(5):789-93. PubMed ID: 22429259
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study.
    Oberbauer R; Kreis H; Johnson RW; Mota A; Claesson K; Ruiz JC; Wilczek H; Jamieson N; Henriques AC; Paczek L; Chapman J; Burke JT;
    Transplantation; 2003 Jul; 76(2):364-70. PubMed ID: 12883194
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Successful use of immunosuppressive agents for the treatment of progressive rheumatoid interstitial lung disease: a case report].
    Naniwa T; Tomita H; Ninomiya S; Mori T; Maeda S; Kawaguchi H; Sugiura Y; Yoshinouchi T; Morishita M; Ueda R
    Nihon Kokyuki Gakkai Zasshi; 2002 Jan; 40(1):55-60. PubMed ID: 11925920
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.
    DuBay D; Smith RJ; Qiu KG; Levy GA; Lilly L; Therapondos G
    Liver Transpl; 2008 May; 14(5):651-9. PubMed ID: 18433069
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term effects of cyclosporine in children with idiopathic nephrotic syndrome: a single-centre experience.
    El-Husseini A; El-Basuony F; Mahmoud I; Sheashaa H; Sabry A; Hassan R; Taha N; Hassan N; Sayed-Ahmad N; Sobh M
    Nephrol Dial Transplant; 2005 Nov; 20(11):2433-8. PubMed ID: 16204303
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of calcineurin inhibitors on bone metabolism in primary kidney transplant patients.
    Bozkaya G; Nart A; Uslu A; Onman T; Aykas A; Doğan M; Karaca B
    Transplant Proc; 2008; 40(1):151-5. PubMed ID: 18261573
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Health-related quality-of-life outcomes of sirolimus-treated kidney transplant patients after elimination of cyclosporine A: results of a 2-year randomized clinical trial.
    Oberbauer R; Hutchison B; Eris J; Arias M; Claesson K; Mota A; Kreis H; Kleinman L; Wang F; Chen J; Revicki DA;
    Transplantation; 2003 Apr; 75(8):1277-85. PubMed ID: 12717216
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression.
    Hernández D; Miquel R; Porrini E; Fernández A; González-Posada JM; Hortal L; Checa MD; Rodríguez A; García JJ; Rufino M; Torres A
    Transplantation; 2007 Sep; 84(6):706-14. PubMed ID: 17893603
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Efficacy of ab initio immunosuppressive therapy and steroid-sparing effect in interstitial lung disease associated with antisynthetase antibody syndrome].
    Franzolini N; Quartuccio L; De Marchi G; De Vita S
    Reumatismo; 2007; 59(3):202-8. PubMed ID: 17898879
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [A case of amyopathic dermatomyositis with interstitial pneumonia: successful treatment with a combination of prednisolone and cyclosporin A].
    Nakayama S; Fukushima K; Ehara N; Okuno K; Hayashi T; Mukae H; Kitaichi M; Kohno S
    Nihon Kokyuki Gakkai Zasshi; 2004 May; 42(5):429-34. PubMed ID: 15168462
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Polymyositis/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants.
    Takada K; Nagasaka K; Miyasaka N
    Autoimmunity; 2005 Aug; 38(5):383-92. PubMed ID: 16227154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination of everolimus with calcineurin inhibitor medication resulted in post-transplant haemolytic uraemic syndrome in lung transplant recipients--a case series.
    Lovric S; Kielstein JT; Kayser D; Bröcker V; Becker JU; Hiss M; Schiffer M; Sommerwerck U; Haller H; Strüber M; Welte T; Gottlieb J
    Nephrol Dial Transplant; 2011 Sep; 26(9):3032-8. PubMed ID: 21310739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.